N348I in HIV-1 Reverse Transcriptase Decreases Susceptibility to Tenofovir and Etravirine in Combination With Other Resistance Mutations

AIDS - United States
doi 10.1097/qad.0b013e3283315697
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2011English

Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2010English

Selection of Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutations in HIV-1 Subtype C: Evidence of Etravirine Cross-Resistance

AIDS
Infectious DiseasesAllergyImmunology
2011English

Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-Deoxythymidine Through Both RNase H-Dependent and -Independent Mechanisms

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2008English

Quantum Chemical Study of Molecular Recognition Between Etravirine/Rilpivirine and the HIV-1 Reverse Transcriptase

Madridge Journal of Novel Drug Research
2017English

Mutations in the Connection Domain of HIV-1 Reverse Transcriptase Increase 3'-Azido-3'-Deoxythymidine Resistance

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2006English

Combination of Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Required for Resistance to the Carbocyclic Nucleoside 1592U89.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

Anti-Hiv Drugs and Resistance: Inhibitors of HIV-1 Reverse Transcriptase and Protease

2012English

Pharmacokinetics of Etravirine Combined With Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

AIDS Research and Treatment
ImmunologyPublic HealthAllergyEnvironmentalDermatologyInfectious DiseasesOccupational Health
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy